Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Phase II study of induction chemotherapy and chemoradiotherapy with cetuximab in non-metastatic esophageal squamous cell carcinoma
2008-001016-21Phase 2Terminated
- Sponsor
- AGMT
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by AGMT. Primary endpoints: Safety and feasibility and Toxicity (NCI criteria). Started May 2008; status: terminated.
02
Drugs
cetuximab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2008-001016-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001016-21.